Indivior 2022 Opiant Merger Addiction Treatment Leadership

Indivior presents its proposed acquisition of Opiant Pharmaceuticals to strengthen its position in addiction treatment and science. The presentation outlines merger details, expected timelines, and anticipated benefits and synergies from combining the two organizations' capabilities and product pipelines.